L Stewart Massad1, Xianhong Xie, Howard Minkoff, Teresa M Darragh, Gypsyamber D'Souza, Lorraine Sanchez-Keeland, D Heather Watts, Christine Colie, Howard D Strickler. 1. 1Washington University School of Medicine, St. Louis, MO; 2Albert Einstein College of Medicine, Bronx, NY; 3Maimonides Medical Center, Brooklyn, NY; 4University of California, San Francisco, CA; 5Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 6University of Southern California, Los Angeles, CA; 7Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD; and 8Georgetown University, Washington, DC.
Abstract
OBJECTIVE: To estimate the frequency of abnormal Pap and human papillomavirus (HPV) positivity among human immunodeficiency virus (HIV)-seropositive and -seronegative women who have sex with women (WSW). METHODS: Pap and HPV DNA polymerase chain reaction tests were obtained every 6 months from women in a US cohort of HIV-seropositive and -seronegative women. Women who have sex with women were women reporting no male and at least 1 female sex partner for 5 years. They were frequency matched 1:5 to women reporting sex only with men (WSM) and assessed using multivariable generalized estimating equation logistic regression models. RESULTS: Paps at study entry were abnormal in 12 (21%) of 49 HIV-seropositive WSW, 151 (64%) of 245 HIV-seropositive WSM, 3 (9%) of 24 HIV-seronegative WSW, and 16 (11%) of 120 HIV-seronegative WSM. Human papillomavirus was found at entry in 18 (42%) HIV-seropositive WSW, 109 (52%) HIV-seropositive WSM, 6 (27%) HIV-seronegative WSW, and 13 (13%) HIV-seronegative WSM. After controlling for HIV serostatus and CD4 count, WSW had marginally lower odds than WSM of Pap abnormality (odds ratio = 0.59, 95% confidence interval = 0.33-1.03) and of HPV (odds ratio = 0.53, 95% confidence interval = 0.32-0.89). After controlling for partner's gender, HIV seropositivity and lower CD4 count were associated with any HPV, oncogenic HPV, any abnormal Pap result, and high-grade squamous intraepithelial lesion or worse (p < .0001 for all). CONCLUSIONS: Although risks for abnormal Pap and HPV are modestly lower in WSW than in WSM, both are common in HIV-seropositive women regardless of sexual preference. Both WSW and WSM should be screened similarly.
OBJECTIVE: To estimate the frequency of abnormal Pap and human papillomavirus (HPV) positivity among humanimmunodeficiency virus (HIV)-seropositive and -seronegative women who have sex with women (WSW). METHODS:Pap and HPV DNA polymerase chain reaction tests were obtained every 6 months from women in a US cohort of HIV-seropositive and -seronegative women. Women who have sex with women were women reporting no male and at least 1 female sex partner for 5 years. They were frequency matched 1:5 to women reporting sex only with men (WSM) and assessed using multivariable generalized estimating equation logistic regression models. RESULTS:Paps at study entry were abnormal in 12 (21%) of 49 HIV-seropositive WSW, 151 (64%) of 245 HIV-seropositive WSM, 3 (9%) of 24 HIV-seronegative WSW, and 16 (11%) of 120 HIV-seronegative WSM. Human papillomavirus was found at entry in 18 (42%) HIV-seropositive WSW, 109 (52%) HIV-seropositive WSM, 6 (27%) HIV-seronegative WSW, and 13 (13%) HIV-seronegative WSM. After controlling for HIV serostatus and CD4 count, WSW had marginally lower odds than WSM of Pap abnormality (odds ratio = 0.59, 95% confidence interval = 0.33-1.03) and of HPV (odds ratio = 0.53, 95% confidence interval = 0.32-0.89). After controlling for partner's gender, HIV seropositivity and lower CD4 count were associated with any HPV, oncogenic HPV, any abnormal Pap result, and high-grade squamous intraepithelial lesion or worse (p < .0001 for all). CONCLUSIONS: Although risks for abnormal Pap and HPV are modestly lower in WSW than in WSM, both are common in HIV-seropositivewomen regardless of sexual preference. Both WSW and WSM should be screened similarly.
Authors: J M Palefsky; H Minkoff; L A Kalish; A Levine; H S Sacks; P Garcia; M Young; S Melnick; P Miotti; R Burk Journal: J Natl Cancer Inst Date: 1999-02-03 Impact factor: 13.506
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Howard D Strickler; Robert D Burk; Melissa Fazzari; Kathryn Anastos; Howard Minkoff; L Stewart Massad; Charles Hall; Melanie Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Nicolas F Schlecht; Sandra Melnick; Joel M Palefsky Journal: J Natl Cancer Inst Date: 2005-04-20 Impact factor: 13.506
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: L Stewart Massad; Eric C Seaberg; Rodney L Wright; Teresa Darragh; Yi-Chun Lee; Christine Colie; Robert Burk; Howard D Strickler; D Heather Watts Journal: Obstet Gynecol Date: 2008-06 Impact factor: 7.661
Authors: Madeline B Deutsch; Sari L Reisner; Sarah Peitzmeier; Jennifer Potter; Dana Pardee; Jaclyn M W Hughto Journal: Sex Transm Dis Date: 2020-01 Impact factor: 3.868